Lanreotide

Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome[1][2].

Product Specifications

CAS Number

[108736-35-2]

Product Name Alternative

BIM 23014

UNSPSC

12352209

Hazard Statement

H302, H312, H332

Target

Somatostatin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/lanreotide.html

Purity

98.86

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 25 mg/mL

Smiles

O=C([C@@H](NC([C@@](CSSC[C@@H](C(N[C@H](C(N)=O)[C@H](O)C)=O)NC([C@H](C(C)C)NC([C@@](CCCCN)([H])NC1=O)=O)=O)([H])NC([C@H](N)CC2=CC3=CC=CC=C3C=C2)=O)=O)CC4=CC=C(O)C=C4)N[C@@H]1CC5=CNC6=C5C=CC=C6

Molecular Formula

C54H69N11O10S2

Molecular Weight

1096.32

Precautions

H302, H312, H332

References & Citations

[1]Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16 (3) :1045-55.|[2]Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf) . 2003 Jul;59 (1) :115-28.